Drug intelligence / Profile preview

wee1 inhibitor ii

Development stage
Unknown
Lead developer
Merck KGaA
Modality
Small Molecules
Administration
Intraperitoneal
01

Overview

Wee1 Inhibitor II is a potent, cell-permeable, and highly selective small molecule inhibitor of the Wee1 kinase, a critical regulator of the G2/M cell cycle checkpoint. By inhibiting Wee1, the compound prevents the inhibitory phosphorylation of Cdc2 (CDK1) at Tyr15, which promotes premature entry into mitosis and can lead to mitotic catastrophe in DNA-damaged cells. While primarily utilized as a research tool in oncology to study cell cycle arrest and DNA damage repair mechanisms, recent neurobiology research has identified its role in modulating the Nav1.2 channelosome. Specifically, Wee1 Inhibitor II has been shown to disrupt the interaction between fibroblast growth factor 14 (FGF14) and the voltage-gated sodium channel Nav1.2, thereby influencing neuronal excitability and firing properties. It is widely used in vitro and in cell-based assays to interrogate Wee1-mediated signaling pathways.

Other names
6-butyl-4-(2-chlorophenyl)-2-((4-(diethylamino)butyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-oneCalbiochem 681291Calbiochem681291Calbiochem-681291
02

Targets

CHEK1 (Checkpoint kinase 1)WEE1 (WEE1 G2 checkpoint kinase)

Beyond the preview

Go deeper on wee1 inhibitor ii.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on wee1 inhibitor ii.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call